484 related articles for article (PubMed ID: 37189112)
1. Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.
Kakavandi S; Zare I; VaezJalali M; Dadashi M; Azarian M; Akbari A; Ramezani Farani M; Zalpoor H; Hajikhani B
Cell Commun Signal; 2023 May; 21(1):110. PubMed ID: 37189112
[TBL] [Abstract][Full Text] [Related]
2. Host Cell and SARS-CoV-2-Associated Molecular Structures and Factors as Potential Therapeutic Targets.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Roshan R; Azam F; Mehta J; Handu S; Prasad R; Jain N; Pandey AK; Dhamija P
Cells; 2021 Sep; 10(9):. PubMed ID: 34572076
[TBL] [Abstract][Full Text] [Related]
3. The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.
Zalpoor H; Akbari A; Samei A; Forghaniesfidvajani R; Kamali M; Afzalnia A; Manshouri S; Heidari F; Pornour M; Khoshmirsafa M; Aazami H; Seif F
Cell Mol Biol Lett; 2022 Feb; 27(1):10. PubMed ID: 35109786
[TBL] [Abstract][Full Text] [Related]
4. Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2.
Patil S; Alzahrani KJ; Banjer HJ; Halawani IF; Alzahrani H; Altayar MA; Albogami S; Angeles RF; Hassan AAA; Bhandi S; Raj AT
J Infect Public Health; 2022 Jul; 15(7):781-787. PubMed ID: 35738053
[TBL] [Abstract][Full Text] [Related]
5. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
6. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.
Liu Z; Xiao X; Wei X; Li J; Yang J; Tan H; Zhu J; Zhang Q; Wu J; Liu L
J Med Virol; 2020 Jun; 92(6):595-601. PubMed ID: 32100877
[TBL] [Abstract][Full Text] [Related]
7. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
[TBL] [Abstract][Full Text] [Related]
10. Interfacial Water in the SARS Spike Protein: Investigating the Interaction with Human ACE2 Receptor and In Vitro Uptake in A549 Cells.
Singh AV; Kayal A; Malik A; Maharjan RS; Dietrich P; Thissen A; Siewert K; Curato C; Pande K; Prahlad D; Kulkarni N; Laux P; Luch A
Langmuir; 2022 Jul; 38(26):7976-7988. PubMed ID: 35736838
[TBL] [Abstract][Full Text] [Related]
11. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
12. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
14. An
Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y
J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
Ali A; Vijayan R
Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
[TBL] [Abstract][Full Text] [Related]
16. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
[TBL] [Abstract][Full Text] [Related]
17. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.
Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I
Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
20. ACE2, B
Zhang Y; Yan R; Zhou Q
Curr Opin Struct Biol; 2022 Jun; 74():102388. PubMed ID: 35584583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
